Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Phase 1, Double-Blind, Placebo-Controlled Crossover Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants

To see complete record on, please visit this link

Id: NCT05049343

Organisation Name: Sage Therapeutics

Overal Status: Completed

Start Date: September 21, 2021

Last Update: January 21, 2022

Lead Sponsor: Sage Therapeutics

Brief Summary: The primary purpose of this study is to determine functional target engagement of SAGE-904 using electrophysiological paradigms before and after ketamine administration.

  • Healthy Volunteer

Total execution time in seconds: 0.20965790748596